Bastide Le Confort Médical : A good level to buy
Entry price | Target | Stop-loss | Potential |
---|
€42.5 |
€46.3 |
€41.3 |
+8.94% |
---|
The selling pressure regarding Bastide Le Confort Médical shares could subside shortly. In fact, the support area that is currently being tested around 39.3 EUR has come into play and could, at least in the short term, keep the downside pressure at bay.
Strengths● Given the positive cash flows generated by its business, the company's valuation level is an asset.
● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
● The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
● Analyst opinion has improved significantly over the past four months.
Weaknesses● The company sustains low margins.
● The company is in debt and has limited leeway for investment
● The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
● Over the past twelve months, analysts' consensus has been significantly revised downwards.
● Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.